» Articles » PMID: 2988376

Immunologic Response of Sheep to Inactivated and Virulent Bluetongue Virus

Overview
Journal Am J Vet Res
Date 1985 May 1
PMID 2988376
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Humoral and cellular immune responses of sheep to inactivated and virulent bluetongue virus (BTV) were studied. All sheep inoculated with inactivated BTV developed BTV group-specific nonneutralizing antibodies, as determined by agar-gel immunodiffusion. The development of group-specific, nonneutralizing, complement-fixing antibodies was variable and appeared to be dependent on immunizing BTV serotype, sheep breed, and individual variation. Virus-neutralizing antibodies were never detected after inoculation with the inactivated BTV. In vitro lymphocyte stimulation to BTV soluble antigen was observed with cells from all inoculated Warhill sheep and with cells from 1 of 3 inoculated Suffolk cross sheep. Complement-fixation titers did not appear to correlate with the degree of protection observed, ie, duration of postchallenge-exposure viremia. The development of postchallenge-exposure neutralizing antibody titer was inversely correlated to protective immunity. The development of a response to BTV antigen in the lymphocyte-stimulation test associated most closely with protection. Warhill sheep were afforded better protection, by inoculation with inactivated BTV, to live virus challenge exposure than were the Suffolk cross sheep. Approximately 30% of the inoculated Suffolk cross sheep responded to challenge exposure with intensified clinical signs of blue-tongue, compared with the challenge-exposed control sheep of the same breed.

Citing Articles

Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice.

Jimenez-Cabello L, Utrilla-Trigo S, Rodriguez-Sabando K, Carra-Valenzuela A, Illescas-Amo M, Calvo-Pinilla E J Virol. 2024; 98(12):e0168724.

PMID: 39508577 PMC: 11650994. DOI: 10.1128/jvi.01687-24.


Defining correlates of protection for mammalian livestock vaccines against high-priority viral diseases.

Davis S, Jia F, Wright Q, Islam M, Bean A, Layton D Front Immunol. 2024; 15:1397780.

PMID: 39100679 PMC: 11294087. DOI: 10.3389/fimmu.2024.1397780.


Comprehensive immune profiling reveals that infection activates immune checkpoints during acute T cell immunosuppression.

Louloudes-Lazaro A, Rojas J, Garcia-Garcia I, Rodriguez-Martin D, Morel E, Martin V Front Immunol. 2023; 14:1255803.

PMID: 37920474 PMC: 10619675. DOI: 10.3389/fimmu.2023.1255803.


Vaccination With Recombinant Adenoviruses Expressing the Bluetongue Virus Subunits VP7 and VP2 Provides Protection Against Heterologous Virus Challenge.

Rojas J, Barba-Moreno D, Avia M, Sevilla N, Martin V Front Vet Sci. 2021; 8:645561.

PMID: 33778041 PMC: 7987666. DOI: 10.3389/fvets.2021.645561.


Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): bluetongue.

More S, Bicout D, Botner A, Butterworth A, Depner K, Edwards S EFSA J. 2020; 15(8):e04957.

PMID: 32625623 PMC: 7010010. DOI: 10.2903/j.efsa.2017.4957.